交易 Kyntra Bio Inc - KYNB 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.35
• 长仓隔夜仓息调整: -0.02151%
• 短仓隔夜仓息调整: -0.00071%
• 隔夜调整仓息时间: 21:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 6.49
• 开仓: 6.49
• 1 年变化: 2063.33%
• 日区间: 6.19 - 6.49

交易 Kyntra Bio Inc - KYNB 差价合约

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.